Retrospective analysis of candidate predictive tumor biomarkers (BMs) for efficacy in the GOG-0218 trial evaluating front-line carboplatin–paclitaxel (CP) ± bevacizumab (BEV) for epithelial ovarian cancer (EOC).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 5505-5505 ◽  
Author(s):  
Michael J. Birrer ◽  
YounJeong Choi ◽  
Mark F. Brady ◽  
Robert S. Mannel ◽  
Robert Allen Burger ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Retrospective Analysis ◽  
Tumor Biomarkers ◽  
Front Line

scholarly journals Diagnostic value of tumor biomarkers CA125 and CA72-4 in differentiation of epithelial ovarian cancer and endometrioma

2018 ◽  
Vol 29 (8) ◽  
Author(s):  
Jafari Shobeiri Mehri ◽  
Sepasi Farnaz ◽  
Dastranj Tabrizi Ali ◽  
Mostafa Gharabaghi Parvin ◽  
Ouladsahebmadarek Elaheh ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Diagnostic Value ◽  
Tumor Biomarkers

Front-Line Treatment of Epithelial Ovarian Cancer

2005 ◽  
Vol 4 (4) ◽  
pp. 221-231 ◽  
Author(s):  
Lainie Martin ◽  
Russell J Schilder
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Line Treatment ◽  
Front Line

scholarly journals Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis

2019 ◽  
Vol 150 (6) ◽  
pp. 575 ◽  
Author(s):  
Lalit Kumar ◽  
Aparna Sharma ◽  
PrabhatSingh Malik ◽  
Sachin Khurana ◽  
Sunesh Kumar ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Retrospective Analysis ◽  
Metronomic Chemotherapy

scholarly journals Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment

Cancers ◽  
2021 ◽  
Vol 13 (24) ◽  
pp. 6239
Author(s):  
Joan Tymon-Rosario ◽  
Naomi N. Adjei ◽  
Dana M. Roque ◽  
Alessandro D. Santin
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Clinical Data ◽  
Standard Of Care ◽  
Therapeutic Agents ◽  
Chemotherapeutic Agents ◽  
Front Line ◽  
Current Standard ◽  
The Past ◽  
Taxane Resistance

Taxanes and epothilones are chemotherapeutic agents that ultimately lead to cell death through inhibition of normal microtubular function. This review summarizes the literature demonstrating their current use and potential promise as therapeutic agents in the treatment of epithelial ovarian cancer (EOC), as well as putative mechanisms of resistance. Historically, taxanes have become the standard of care in the front-line and recurrent treatment of epithelial ovarian cancer. In the past few years, epothilones (i.e., ixabepilone) have become of interest as they may retain activity in taxane-treated patients since they harbor several features that may overcome mechanisms of taxane resistance. Clinical data now support the use of ixabepilone in the treatment of platinum-resistant or refractory ovarian cancer. Clinical data strongly support the use of microtubule-interfering drugs alone or in combination in the treatment of epithelial ovarian cancer. Ongoing clinical trials will shed further light into the potential of making these drugs part of current standard practice.

Sign in / Sign up

Export Citation Format

Share Document